As you may be aware, the California trial that was set for January 23, 2018 (Lauris v. Novartis AG) was continued by the Judge. The judge wanted additional time to review the voluminous documents and pretrial motions. We are optimistic that the case will be reset between now and October 2018.
Since the continuation of the trial date, we have engaged in settlement discussions with defense counsel regarding the possibility of global resolution and are in the process of gathering detailed information from clients.
Novartis has long known the risks associated with Tasigna and withheld critical safety information from American physicians, while at the same time providing safety warnings in other countries, such as Canada. The Canadian label for Tasigna was updated with information about arteriosclerosis in 2013. The modifications were made after a review conducted by Health Canada discovered that 277 reports of the condition had been logged with the Novartis global safety database between January 1st, 2005 and January 31, 2013.
We are dedicated to holding Novartis accountable for their reckless desire for profit over safety. Together, we can hold Novartis accountable and will make a difference.
Onder law is providing free Tasigna reviews to individuals who developed arteriosclerosis or related conditions following Tasigna treatment. If you have been affected by this drug and not yet signed up and/or returned your contract and medical authorizations to the firm, we would urge you to do so as soon as possible, so that we can present your claim for potential resolution.